|
|
Post by mnholdem on Apr 19, 2017 10:58:43 GMT -5
Insulin Management System Market Volume Forecast and Value Chain Analysis 2016-2026
April 19th, 2017
Excerpt:
Insulin Management System Market: Overview
Insulin treatment for Type II diabetes holds largest share due to its high prevalence and also availability of variety and advances in insulin management systems available to treat type II diabetes. Also in comparison to recombinant human Insulin there is greater share for insulin analogues due to its higher efficacy with fast and long lasting effects. Moreover in comparison to painful traditional methods of insulin administration by injections, use of inhaled insulins are expected to have larger share in insulin management system market. Inhaled insulin is easy to administer, fast acting and is eliminated from body in less time. Thus, insulin that is affordable, easy to administer, readily available, fast acting with long lasting effect and quick elimination from body is expected to hold strong position in insulin management system market.
Insulin Management System Market: Regional Overview
Region wise, the global regions in Insulin Management System market is classified into, North America, Latin America, Western and Eastern Europe, Asia-Pacific (excluding Japan) and MEA (Brazil, Argentina, Nigeria, Saudi Arabia & Egypt).
Source: www.medgadget.com/2017/04/insulin-management-system-market-volume-forecast-and-value-chain-analysis-2016-2026.html
- America dominates the global insulin management system market due to higher prevalence of diabetes, high income population and also due to significant patent protection for brands of biosimilar insulin.
- Europe holds second largest insulin management system market due to better distribution network for key players in insulin management system market.
- Asia Pacific and MEA are the fastest growing due to adoption of various advancement in insulin management system. Initiatives taken by government in developing countries to provide better healthcare facilities and easy utilization of insulin management system plays a larger role in increasing market for insulin management systems.
|
|
|
|
Post by fanz8967 on Apr 19, 2017 14:26:05 GMT -5
Insulin Management System Market Volume Forecast and Value Chain Analysis 2016-2026
April 19th, 2017
Excerpt:
Insulin Management System Market: Overview
Insulin treatment for Type II diabetes holds largest share due to its high prevalence and also availability of variety and advances in insulin management systems available to treat type II diabetes. Also in comparison to recombinant human Insulin there is greater share for insulin analogues due to its higher efficacy with fast and long lasting effects. Moreover in comparison to painful traditional methods of insulin administration by injections, use of inhaled insulins are expected to have larger share in insulin management system market. Inhaled insulin is easy to administer, fast acting and is eliminated from body in less time. Thus, insulin that is affordable, easy to administer, readily available, fast acting with long lasting effect and quick elimination from body is expected to hold strong position in insulin management system market.
Insulin Management System Market: Regional Overview
Region wise, the global regions in Insulin Management System market is classified into, North America, Latin America, Western and Eastern Europe, Asia-Pacific (excluding Japan) and MEA (Brazil, Argentina, Nigeria, Saudi Arabia & Egypt).
Source: www.medgadget.com/2017/04/insulin-management-system-market-volume-forecast-and-value-chain-analysis-2016-2026.html
- America dominates the global insulin management system market due to higher prevalence of diabetes, high income population and also due to significant patent protection for brands of biosimilar insulin.
- Europe holds second largest insulin management system market due to better distribution network for key players in insulin management system market.
- Asia Pacific and MEA are the fastest growing due to adoption of various advancement in insulin management system. Initiatives taken by government in developing countries to provide better healthcare facilities and easy utilization of insulin management system plays a larger role in increasing market for insulin management systems.
Mannkind is not listed as a key player. Are they expecting one of the BPs to have an inhaled insulin product approved in these markets? |
|
|
|
Post by porkini on Apr 19, 2017 15:04:56 GMT -5
Insulin Management System Market Volume Forecast and Value Chain Analysis 2016-2026
April 19th, 2017
Excerpt:
Insulin Management System Market: Overview
Insulin treatment for Type II diabetes holds largest share due to its high prevalence and also availability of variety and advances in insulin management systems available to treat type II diabetes. Also in comparison to recombinant human Insulin there is greater share for insulin analogues due to its higher efficacy with fast and long lasting effects. Moreover in comparison to painful traditional methods of insulin administration by injections, use of inhaled insulins are expected to have larger share in insulin management system market. Inhaled insulin is easy to administer, fast acting and is eliminated from body in less time. Thus, insulin that is affordable, easy to administer, readily available, fast acting with long lasting effect and quick elimination from body is expected to hold strong position in insulin management system market.
Insulin Management System Market: Regional Overview
Region wise, the global regions in Insulin Management System market is classified into, North America, Latin America, Western and Eastern Europe, Asia-Pacific (excluding Japan) and MEA (Brazil, Argentina, Nigeria, Saudi Arabia & Egypt).
Source: www.medgadget.com/2017/04/insulin-management-system-market-volume-forecast-and-value-chain-analysis-2016-2026.html
- America dominates the global insulin management system market due to higher prevalence of diabetes, high income population and also due to significant patent protection for brands of biosimilar insulin.
- Europe holds second largest insulin management system market due to better distribution network for key players in insulin management system market.
- Asia Pacific and MEA are the fastest growing due to adoption of various advancement in insulin management system. Initiatives taken by government in developing countries to provide better healthcare facilities and easy utilization of insulin management system plays a larger role in increasing market for insulin management systems.
. Are they expecting one of the BPs to have an inhaled insulin product approved in these markets? Excerpt from same article referenced by mnholdem : Insulin Management System Market: Key PlayersEli Lilly and Company, GlaxoSmithKline, Biocon, Sanofi Aventis, Julphar, Novo Nordisk, SemBioSys, and WOCKHARDT, Abbott India Ltd., USV Limited, Torrent Pharmaceuticals Ltd and Piramal Enterprises Limited are key players. |
|
|
|
Post by fanz8967 on Apr 19, 2017 15:09:01 GMT -5
Mannkind is not listed as a key player. Are they expecting one of the BPs to have an inhaled insulin product approved in these markets? Excerpt from same article referenced by mnholdem : Insulin Management System Market: Key PlayersEli Lilly and Company, GlaxoSmithKline, Biocon, Sanofi Aventis, Julphar, Novo Nordisk, SemBioSys, and WOCKHARDT, Abbott India Ltd., USV Limited, Torrent Pharmaceuticals Ltd and Piramal Enterprises Limited are key players. What do you mean? The authors can't know the details of an unannounced deal. Are they speculating or counting on one of these BPs beating MNKD to these markets with a new inhaled insulin product? |
|
|
|
Post by porkini on Apr 19, 2017 15:35:37 GMT -5
Excerpt from same article referenced by mnholdem : Insulin Management System Market: Key PlayersEli Lilly and Company, GlaxoSmithKline, Biocon, Sanofi Aventis, Julphar, Novo Nordisk, SemBioSys, and WOCKHARDT, Abbott India Ltd., USV Limited, Torrent Pharmaceuticals Ltd and Piramal Enterprises Limited are key players. The authors can't know the details of an unannounced deal. Are they speculating or counting on one of these BPs beating MNKD to these markets with a new inhaled insulin product? No opinion was expressed, only an excerpt from the same article for the enjoyment of readers everywhere. Feel free to draw your own conclusions.  |
|
|
|
Post by careful2invest on Apr 19, 2017 16:53:15 GMT -5
Insulin Management System Market Volume Forecast and Value Chain Analysis 2016-2026
April 19th, 2017
Excerpt:
Insulin Management System Market: Overview
Insulin treatment for Type II diabetes holds largest share due to its high prevalence and also availability of variety and advances in insulin management systems available to treat type II diabetes. Also in comparison to recombinant human Insulin there is greater share for insulin analogues due to its higher efficacy with fast and long lasting effects. Moreover in comparison to painful traditional methods of insulin administration by injections, use of inhaled insulins are expected to have larger share in insulin management system market. Inhaled insulin is easy to administer, fast acting and is eliminated from body in less time. Thus, insulin that is affordable, easy to administer, readily available, fast acting with long lasting effect and quick elimination from body is expected to hold strong position in insulin management system market.
Insulin Management System Market: Regional Overview
Region wise, the global regions in Insulin Management System market is classified into, North America, Latin America, Western and Eastern Europe, Asia-Pacific (excluding Japan) and MEA (Brazil, Argentina, Nigeria, Saudi Arabia & Egypt).
Source: www.medgadget.com/2017/04/insulin-management-system-market-volume-forecast-and-value-chain-analysis-2016-2026.html
- America dominates the global insulin management system market due to higher prevalence of diabetes, high income population and also due to significant patent protection for brands of biosimilar insulin.
- Europe holds second largest insulin management system market due to better distribution network for key players in insulin management system market.
- Asia Pacific and MEA are the fastest growing due to adoption of various advancement in insulin management system. Initiatives taken by government in developing countries to provide better healthcare facilities and easy utilization of insulin management system plays a larger role in increasing market for insulin management systems.
Mannkind is not listed as a key player. Are they expecting one of the BPs to have an inhaled insulin product approved in these markets? Again...It just does not make sense! That's MNKD |
|
|
|
Post by sayhey24 on Apr 19, 2017 19:45:32 GMT -5
If you really want to know why MNKD was not listed you can asked the analyst. www.futuremarketinsights.com/reports/insulin-management-system-marketThe report is due out in June. For anyone who does NOT know the history of MNKD and their struggle with afrezza the report would seem to make perfect sense. 90% of the market are T2's and the only reason all T2s are not put on insulin from the very beginning is it is seen as dangerous, it takes training, its expensive and is associated with needles. If you could solve these issues by having a solution which virtually eliminates severe hypoglycemia, is easy to administer and in the end saves lives and money that would seem like a solution worth its weight in gold. Why would anyone risk the current pills and potions just to delay insulin use when early insulin use can put many T2s into remission and avoid future complications and health costs? Now, the T2 market is not MNKDs focus. Maybe that is why they are not listed. That is the market Stefan Schwarz thought was the perfect fit for afrezza. The last I checked he was working for SNY doing something with Onduo. |
|
|
|
Post by peppy on Apr 19, 2017 20:01:40 GMT -5
If you really want to know why MNKD was not listed you can asked the analyst. www.futuremarketinsights.com/reports/insulin-management-system-marketThe report is due out in June. For anyone who does NOT know the history of MNKD and their struggle with afrezza the report would seem to make perfect sense. 90% of the market are T2's and the only reason all T2s are not put on insulin from the very beginning is it is seen as dangerous, it takes training, its expensive and is associated with needles. If you could solve these issues by having a solution which virtually eliminates severe hypoglycemia, is easy to administer and in the end saves lives and money that would seem like a solution worth its weight in gold. Why would anyone risk the current pills and potions just to delay insulin use when early insulin use can put many T2s into remission and avoid future complications and health costs? Now, the T2 market is not MNKDs focus. Maybe that is why they are not listed. That is the market Stefan Schwarz thought was the perfect fit for afrezza. The last I checked he was working for SNY doing something with Onduo. quote: T2s are not put on insulin from the very beginning is it is seen as dangerous, it takes training, its expensive and is associated with needles. If you could solve these issues by having a solution which virtually eliminates severe hypoglycemia, is easy to administer and in the end saves lives and money that would seem like a solution worth its weight in gold.
Reply: It is too expensive especially when health care wants all the money? The myth is that healthcare wants us to get healthy.
|
|
|
|
Post by kc on Apr 19, 2017 23:10:53 GMT -5
Insulin Management System Market Volume Forecast and Value Chain Analysis 2016-2026
April 19th, 2017
Excerpt:
Insulin Management System Market: Overview
Insulin treatment for Type II diabetes holds largest share due to its high prevalence and also availability of variety and advances in insulin management systems available to treat type II diabetes. Also in comparison to recombinant human Insulin there is greater share for insulin analogues due to its higher efficacy with fast and long lasting effects. Moreover in comparison to painful traditional methods of insulin administration by injections, use of inhaled insulins are expected to have larger share in insulin management system market. Inhaled insulin is easy to administer, fast acting and is eliminated from body in less time. Thus, insulin that is affordable, easy to administer, readily available, fast acting with long lasting effect and quick elimination from body is expected to hold strong position in insulin management system market.
Insulin Management System Market: Regional Overview
Region wise, the global regions in Insulin Management System market is classified into, North America, Latin America, Western and Eastern Europe, Asia-Pacific (excluding Japan) and MEA (Brazil, Argentina, Nigeria, Saudi Arabia & Egypt).
Source: www.medgadget.com/2017/04/insulin-management-system-market-volume-forecast-and-value-chain-analysis-2016-2026.html
- America dominates the global insulin management system market due to higher prevalence of diabetes, high income population and also due to significant patent protection for brands of biosimilar insulin.
- Europe holds second largest insulin management system market due to better distribution network for key players in insulin management system market.
- Asia Pacific and MEA are the fastest growing due to adoption of various advancement in insulin management system. Initiatives taken by government in developing countries to provide better healthcare facilities and easy utilization of insulin management system plays a larger role in increasing market for insulin management systems.
Mannkind is not listed as a key player. Are they expecting one of the BPs to have an inhaled insulin product approved in these markets? Key Player is a company with some market share in the diabetes space. They're not mentioned as they Are not key player. |
|
|
|
Post by mango on Apr 19, 2017 23:39:58 GMT -5
I wouldn't give a second thought about why MannKind is not listed. FMI is a syndicated research report company whose sole objective is to drive in traffic to their website. They publish tons of articles daily and their main headquarters is located in India. They have 2 more branches, one in New York and another in the UK. They are a company whose intent is to pollute search engine results and generate traffic to their website and affiliated websites. They are quack. • Mr. Abhishek Budholiya's work history and education details explains this. • Mr. Abhishek Budholiya's education was received from a publicly traded "school", I mean company, that trades on the National Stock Exchange of India and also on the Asian BSE (formerly called Bombay Stock Exchange Ltd.) • Future Market Insights hires exclusively from the NIIT and other "institutions". • Your degree from the publicly traded Indian company, National Institute of Information Technology Limited, can be obtained from one of these convenient locations: www.shocase.com/go/user/qccac51xop9yS1gersm7iz5ls4www.futuremarketinsights.com/media/brochures/future-market-insights.pdfen.m.wikipedia.org/wiki/NIIT |
|
|
|
Post by akemp3000 on Apr 20, 2017 6:34:57 GMT -5
The list was for Insulin Management Systems, or key insulin players and would be correct based on insulin market share. It was not a list of forthcoming inhaled insulin players.
|
|
|
|
Post by careful2invest on Apr 20, 2017 7:17:27 GMT -5
The list was for Insulin Management Systems, or key insulin players and would be correct based on insulin market share. It was not a list of forthcoming inhaled insulin players. Yet in the article, they write... "use of inhaled insulins are expected to have larger share in insulin management system market. Inhaled insulin is easy to administer, fast acting and is eliminated from body in less time. Thus, insulin that is affordable, easy to administer, readily available, fast acting with long lasting effect and quick elimination from body is expected to hold strong position in insulin management system market. But no mention of AFREZZA by name. What other "key players" are in the "inhaled insulin" market? It just does not make sense! |
|
|
|
Post by mnholdem on Apr 20, 2017 8:01:14 GMT -5
The report was about more than inhaled insulin:
Market: Segmentation
The market for global Insulin management system is classified on the basis of disease indication, product type, mode of action, route of administration, end user and geography.
Based on product type, the market for global insulin management system is segmented into the following:
- Needle and syringe.
- Insulin Pen Injectors.
- Insulin jet injectors.
- External Insulin pumps.
- Implantable pumps.
- Insulin patches.
- Islet cell transplantation.
- Insulin inhalers.
I had only posted an excerpt and link to the entire report.
MannKind's name was omitted simply because is not a major player in the diabetes treatment market. That's no big deal to me. It's just the current reality. However, there is a belief among many (and not just investors) that MannKind could take its place among the "major" players once Afrezza becomes widely accepted by patients and the industry.
Besides, there are other biopharms working on inhaled insulin, such as Dance BioPharm's Dance-501.
dancebiopharm.com/
|
|
